GenVec picks up the pieces after trial halt; Merck preps Ebola vaccine for submission;

@FierceBiotech: Top 10 mega-rounds fuel record VC pace, with a distinctly ex-U.S. biotech accent. Report | Follow @FierceBiotech

@JohnCFierce: Seeing some silly reactions to $ZFGN this a.m. No trial that ends in a complete hold is a "success," and efficacy data won't lift that hold. | Follow @JohnCFierce

@DamianFierce: Index Ventures' official Dick Costolo announcement is a link to his tweets of screenshots from his notes app. Website | Follow @DamianFierce

> GenVec ($GNVC) is working to move on after a safety issue led partner Novartis ($NVS) to halt clinical development of its lead asset, a treatment for hearing loss. More

> Merck ($MRK) is planning to file its Ebola vaccine for global approvals next year. Story

> U.K. biotech Immunocore started a Phase Ib/II trial combining its immuno-oncology candidate IMCgp100 with durvalumab and tremelimumab, two cancer therapies in development by AstraZeneca ($AZN). News

Medical Device News

@FierceMedDev: IBM bets its future on machine learning and Watson Health. More | Follow @FierceMedDev

@VarunSaxena2: Interesting article in @TheEconomist. Which lifesci hub do you think is no. 1? Poll | Follow @VarunSaxena2

@EmilyWFierce: Roche blindsided by off-label Avastin fallout in #India. Story | Follow @EmilyWFierce

> Spanish researchers prototype robotic arm for shoulder rehabilitation. More

> Randomized trial finds smartphone-enabled patient monitors don't decrease healthcare utilization. Article

Pharma News

@FiercePharma: Roche blindsided by off-label Avastin fallout in India. More | Follow @FiercePharma

@CarlyHFierce: ICYMI: Big question for Pfizer: Will Enbrel's EU biosim bring on the pain? Story | Follow @CarlyHFierce

> Novartis extends lead on psoriasis rivals with a pair of new Cosentyx approvals. More

> NHS watchdog takes issue with Pfizer exec's new role on foundation trust's board. News

> Pfizer looks to Russian partnership to produce some of its meds there, report says. Story

Biotech Research News

> New study offers researchers a guide to making next-gen TB drugs. More

> Allergan highlights preclinical evidence of cognitive safety for fast-acting depression drug. News

> Scripps team spots a new mechanism that drives Celgene's ozanimod, potential rivals. Story

> Columbia U. team refines replacement cells for injured hearts. Article

> Study presents a fresh opportunity for early ovarian cancer diagnosis. Report

Pharma Marketing News

> Glass half empty? Pharma staffers about as content as average Americans, survey finds. Story

> Pharma's December TV spending sags; Pfizer and BMS' Eliquis rises to top. News

> Takeda's U.K. unit brings sales force in-house to boost efforts in oncology, IBD. Report

> Merck & Co. sues Merck KGaA over naming rights in transatlantic tug-of-war. Article

> Minds + Assembly jumps off big pharma agencies, aims for 'breakthrough' work with Orexo. More

Vaccines News

> Merck to submit Ebola vaccine for regulatory approval in 2017. Story

> FDA expands indication for GSK's Hib vaccine, Hiberix. News

> Dengue vaccine developed at NIH enters PhIII in Brazil. More

> Baltimore's Profectus BioSciences starts PhI trial of Ebola vaccine. Report

> Sanofi working with health authorities on dengue vaccine strategies. Article

Suggested Articles

Antivirals from Roche, Bristol Myers Squibb, Viiv and Gilead, or modified versions of them, could prove effective against COVID-19, researchers said.

After posting positive data that showed it could help slow down the degenerative ALS disease, Amylyx has been given a $30 million boost.

Sumitomo is looking to the merged pipeline to help offset the anticipated impact of the arrival of generic competitors to bipolar drug Latuda.